The scale of the problem ENDPOINT addresses is difficult to overstate. Lymphatic filariasis and onchocerciasis are both caused by filarial parasitic worms transmitted to humans by insect vectors — mosquitoes in the case of lymphatic filariasis and blackflies in the case of onchocerciasis. Together, these infections affect an estimated 78 million people, with a further one billion judged to be at risk. Lymphatic filariasis, historically known as elephantiasis, damages the lymphatic system and produces chronic swelling of the limbs and genitals, profound disfigurement and social stigma. Onchocerciasis, or river blindness, is the second leading infectious cause of blindness worldwide and also causes severe, debilitating skin disease. Beyond the direct clinical burden, both diseases significantly undermine economic prosperity in endemic communities, trapping affected households in cycles of poverty that mass drug administration alone has struggled to break.

As a product development partnership, ENDPOINT occupies a distinctive niche in the global health architecture. Rather than conducting basic research or delivering existing interventions, PDPs are structured to advance a pipeline of candidate products — in this case innovative diagnostics and treatments — while simultaneously generating evidence on their acceptability and feasibility within affected communities and health systems. The programme will also map potential policy and regulatory pathways, a step that is often neglected in early-stage development but which determines whether a promising tool ever reaches the patients who need it. This integrated approach reflects a growing recognition within the neglected tropical disease field that technical efficacy is only one ingredient of elimination; a diagnostic that communities will not use, or a drug regimen that health systems cannot deliver, will not move the needle regardless of its laboratory performance.

Professor Joseph Turner, co-director of LSTM’s Centre for Drugs and Diagnostics and research director of the partnership, framed the funding as a critical endorsement of the institution’s filarial portfolio. He expressed immense gratitude for what he described as a valuable FCDO investment in the CDD iiCON filarial NTDs product development portfolio, noting that the pipeline of diagnostic and therapeutic candidates had been selected specifically to overcome barriers that currently stand in the way of lymphatic filariasis and onchocerciasis elimination. Crucially, he emphasised that candidate products will be evaluated not only for effectiveness but also for their acceptability to the communities that would use them, with the results feeding directly into the refinement and acceleration of their onward development. That feedback loop between end users and product developers is one of the defining features of the ENDPOINT model.

The partnership’s portfolio comprises three complementary projects, each targeting a different bottleneck in the elimination effort. The first is a wearable microwave biosensor diagnostic intended to support non-invasive detection and surveillance of lymphatic filariasis in Nepal. Conventional diagnosis of filarial infections typically relies on blood samples or antigen tests that must be administered by trained personnel, which complicates large-scale surveillance in remote endemic areas. A wearable biosensor that can detect infection markers without invasive sampling could transform monitoring, allowing health authorities to track transmission in real time and to verify whether elimination targets have genuinely been achieved — a requirement that becomes increasingly important as countries approach the endgame of their elimination programmes.

The second project repurposes the oral antibiotic fusidic acid as a shorter-course treatment for onchocerciasis, building on the LSTM-led FAME study. Repurposing established drugs is an attractive strategy in neglected tropical disease research because decades of clinical use provide a well-characterised safety profile, and existing manufacturing and regulatory infrastructure can dramatically shorten the path to deployment. Fusidic acid belongs to a class of antibiotics that act against the Wolbachia bacteria, endosymbionts that many filarial worms depend upon for their survival and fertility. Depleting Wolbachia with antibiotics renders the adult worms sterile and ultimately kills them, addressing the root of the infection rather than merely the larval stages targeted by the standard drug ivermectin. A shorter treatment course would make antibiotic therapy far more practical for mass deployment in resource-limited settings.

The third project, conducted in the United Kingdom, involves the early development of a new class of fast-acting anti-Wolbachia drug candidates. These compounds hold potential to treat or prevent onchocerciasis and lymphatic filariasis, and — notably — veterinary zoonotic filariasis as well. Zoonotic filarial infections, in which parasites normally circulating in animals infect humans, represent an underappreciated reservoir that could complicate elimination efforts; a drug class effective across both human and animal filariae would therefore carry strategic value beyond the two headline diseases. Fast-acting anti-Wolbachia agents would also address one of the principal limitations of existing antibiotic regimens, which require weeks of daily dosing and are consequently ill-suited to community-wide campaigns.

Dr Rachael Thomson, ENDPOINT’s chief executive, described the funding award as a real achievement for both ENDPOINT and LSTM, saying that the investment strengthens the global research pipeline for neglected tropical diseases and reinforces the partnership’s commitment to delivering equitable, impactful solutions for affected communities. Her emphasis on equity speaks to a persistent criticism of global health research, in which diseases concentrated in low-income countries have historically attracted a fraction of the funding devoted to conditions prevalent in wealthy nations. By embedding partners in Nepal and Cameroon as full participants in product development rather than merely as trial sites, ENDPOINT aims to strengthen national research and development capacity in endemic countries, leaving behind durable scientific infrastructure alongside the products themselves.

ENDPOINT does not stand alone. It dovetails with FAME, a complementary clinical trial funded by a £4.9 million award from the European and Developing Countries Clinical Trials Partnership, with additional support from the Drugs for Neglected Diseases initiative. FAME is generating critical evidence on the potential of repurposing fusidic acid to treat onchocerciasis and on the future uptake of antibiotic-based tools for filarial disease elimination more broadly. Taken together, ENDPOINT and FAME represent nearly £9.4 million in new investment, a figure that reaffirms LSTM’s long-standing leadership in research and development for filarial neglected tropical diseases. The pairing of an early-stage product development partnership with a late-stage clinical trial is itself a deliberate design choice, ensuring that discoveries made under ENDPOINT can be shepherded along a defined development pathway rather than stalling at the so-called valley of death between laboratory and clinic.

The announcement arrives at a pivotal moment for the neglected tropical disease community. The World Health Organization’s road map for 2021 to 2030 set ambitious elimination targets for lymphatic filariasis and onchocerciasis, and while mass drug administration has driven down transmission in many endemic countries, progress has stalled in others where existing tools are insufficient to finish the job. New diagnostics capable of confirming interruption of transmission, and new treatments capable of killing or sterilising adult worms, are widely regarded as the missing instruments for the final phase of elimination. By combining cutting-edge technologies such as wearable biosensing and novel anti-Wolbachia pharmacology with strong in-country partnerships and a systematic focus on acceptability, feasibility and regulatory readiness, ENDPOINT aims to generate the high-quality evidence needed to de-risk scalable solutions. For the 78 million people already living with these diseases and the billion more at risk, the partnership represents a tangible step toward tools that could finally close the chapter on two of humanity’s most ancient afflictions.

Subject of Research: Development of new diagnostics and treatments for the filarial neglected tropical diseases lymphatic filariasis and onchocerciasis

Article Title: LSTM announces new £4.5 million partnership to tackle neglected tropical diseases

Article References: LSTM announces new £4.5 million partnership to tackle neglected tropical diseases. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: neglected tropical diseases, lymphatic filariasis, onchocerciasis, Liverpool School of Tropical Medicine, ENDPOINT, Wolbachia, fusidic acid, diagnostics, drug development, UK aid, FCDO, river blindness